Self-assembling lipid modified glycol-split heparin nanoparticles suppress lipopolysaccharide-induced inflammation through TLR4-NF-κB signaling

Journal of Controlled Release

Volumn 194, Issue , 2014, Pages 332-340

  Babazada, Hasan ^a   Yamashita, Fumiyoshi ^a   Yanamoto, Shinya ^a   Hashida, Mitsuru ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Desulfation; Heparin nanoparticles; Inflammation; Macrophage; Nuclear factor B; Toll like receptors

Indexed keywords

ALKANOLAMINES; GLYCOLS; MACROPHAGES; NANOPARTICLES; PATHOLOGY; PHYSICOCHEMICAL PROPERTIES; POLYSACCHARIDES;

ANTI-INFLAMMATORY ACTIVITY; ANTI-INFLAMMATORY EFFECTS; DESULFATION; INFLAMMATION; NUCLEAR FACTORS; PRO-INFLAMMATORY CYTOKINES; STRUCTURE ACTIVITY RELATIONSHIPS; TOLL-LIKE RECEPTORS;

DRUG DELIVERY;

CYTOKINE; DRUG CARRIER; ERYTHROMYCIN ESTOLATE; GLUCOSAMINE; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; NANOPARTICLE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; GLYCOL; LIPID; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; IC50; MACROPHAGE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C3H MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FEMALE; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PARTICLE SIZE; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL SURVIVAL; CYTOKINES; FEMALE; GLYCOLS; HEPARIN; LIPIDS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C3H; MICE, INBRED ICR; NF-KAPPA B; PARTICLE SIZE; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907707901     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.09.011     Document Type: Article

References (48)

1. M.M. Kemp, and R.J. Linhardt Heparin-based nanoparticles Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2 2010 77 87
2. C. Chauvierre, D. Labarre, P. Couvreur, and C. Vauthier Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles Pharm. Res. 20 2003 1786 1793
3. C. Passirani, G. Barratt, J.-P. Devissaguet, and D. Labarre Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system Life Sci. 62 1998 775 785
4. C. Passirani, G. Barratt, J.-P. Devissaguet, and D. Labarre Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) Pharm. Res. 15 1998 1046 1050
5. K. Park, G.Y. Lee, Y.S. Kim, M. Yu, R.W. Park, I.S. Kim, S.Y. Kim, and Y. Byun Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity J. Control. Release 114 2006 300 306
6. C. Chauvierre, M.C. Marden, C. Vauthier, D. Labarre, P. Couvreur, and L. Leclerc Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier Biomaterials 25 2004 3081 3086
7. C. Chauvierre, C. Vauthier, D. Labarre, M.C. Couvreur, and L. Leclerc A new generation of polymer nanoparticles for drug delivery Cell. Mol. Biol. 50 2004 233 239
8. M.M. Kemp, A. Kumar, S. Mousa, T.-J. Park, P. Ajayan, N. Kubotera, S.A. Mousa, and R.J. Linhardt Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities Biomacromolecules 10 2009 589 595
9. Z. Liu, Y. Jiao, F. Liu, and Z. Zhang Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation J. Biomed. Mater. Res. 83A 2007 806 812
10. Y.-H. Lin, C.-H. Chang, Y.-S. Wu, Y.-M. Hsu, S.-F. Chiou, and Y.J. Chen Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy Biomaterials 30 2009 3332 3342
11. S.H. Choi, J.-H. Lee, S.-M. Choi, and T.G. Park Thermally reversible pluronic/heparin nanocapsules exhibiting 1000-fold volume transition Langmuir 22 2006 1758 1762
12. H. Khurshid, S.H. Kim, M.J. Bonder, L. Colak, B. Ali, S.I. Shah, K.L. Kiick, and G.C. Hadjipanayis Development of heparin-coated magnetic nanoparticles for targeted drug delivery applications J. Appl. Phys. 105 2009 (07B308/1-07B308/3)
13. D.J. Tyrrell, A.P. Horne, K.R. Holme, J.M. Preuss, and C.P. Page Heparin in inflammation: potential therapeutic applications beyond anticoagulation Adv. Pharmacol. 46 1999 151 208
14. R.J. Ludwig Therapeutic use of heparin beyond anticoagulation Curr. Drug Discov. Technol. 6 2009 281 289
15. R. Lever, and C.P. Page Novel drug development opportunities for heparin Nat. Rev. Drug Discov. 1 2002 140 148
16. S.M. Lord, B. Tsoi, C. Gunawan, W.Y. Teoh, R. Amal, and J.M. Whitelock Anti-angiogenic activity of heparin functionalised cerium oxide nanoparticles Biomaterials 34 2013 8808 8818
17. K. Park, Y.S. Kim, G.Y. Lee, J.O. Nam, S.K. Lee, R.W. Park, S.Y. Kim, I.S. Kim, and Y. Byun Antiangiogenic effect of bile acid acylated heparin derivative Pharm. Res. 24 1 2007 176 185
18. D.Y. Lee, S.K. Kim, Y.S. Kim, D.H. Son, J.H. Nam, I.S. Kim, R.W. Park, S.Y. Kim, and Y. Byun Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate J. Control. Release 118 2007 310 317
19. J.W. Park, O.C. Jeon, S.K. Kim, T.A. Al-Hilal, S.J. Jin, H.T. Moon, V.C. Yang, S.Y. Kim, and Y. Byun High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives J. Control. Release 148 2010 317 326
20. A. Gaffney, and P. Gaffney Rheumatoid arthritis and heparin Br. J. Rheumatol 35 1996 808
21. P.R. Gaffney, C.T. Doyle, A. Gaffney, J. Hogan, D.P. Hayes, and P. Annis Paradoxical response to heparin in 10 patients with ulcerative colitis Am. J. Gastroenterol. 90 1995 220 223
22. C. Vancheri, C. Mastruzzo, F. Armato, V. Tomaselli, S. Magrì, M.P. Pistorio, M. LaMicela, L. D amico, and N. Crimi Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis J. Allergy Clin. Immunol. 108 2001 703 708
23. E. Young The anti-inflammatory effects of heparin and related compounds Thromb. Res. 122 6 2008 743 752
24. L. Wang, J.R. Brown, A. Varki, and J.D. Esko Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins J. Clin. Invest. 110 2002 127 136
25. S. Akira, K. Takeda, and T. Kaisho Toll-like receptors: critical proteins linking innate and acquired immunity Nat. Immunol. 2 2001 675 680
26. A.N. Theofilopoulos, R. Gonzalez-Quintial, B.R. Lawson, Y.T. Koh, M.E. Stern, D.H. Kono, B. Beutler, and R. Baccala Sensors of the innate immune system: their link to rheumatic diseases Nat. Rev. Rheumatol. 6 2010 146 156
27. S. Walter, M. Letiembre, Y. Liu, H. Heine, B. Penke, W. Hao, B. Bode, N. Manietta, J. Walter, W. Schulz-Schuffer, and K. Fassbender Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease Cell. Physiol. Biochem. 20 2007 947 956
28. T.L. Suber, L. Casciola-Rosen, and A. Rosen Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis Nat. Rev. Rheumatol. 4 2008 201 209
29. A. Lartigue, N. Colliou, S. Calbo, A. François, S. Jacquot, C. Arnoult, F. Tron, D. Gilbert, and P. Musette Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus J. Immunol. 183 2009 6207 6216
30. Jennifer L. Stow, Pei Ching Low, Carolin Offenhäuser, and Daniele Sangermani Cytokine secretion in macrophages and other cells: pathways and mediators Immunobiology 214 2009 601 612
31. J.M. Cavaillon Cytokines and macrophages Biomed. Pharmacother. 48 1994 445 453
32. H.E. Conrad, and Y. Guo Structural analysis of periodate-oxidized heparin Adv. Exp. Med. Biol. 313 1992 31 36
33. P.K. Smith, A.K. Mallia, and G.T. Hermanson Colorimetric method for the assay of heparin content in immobilized heparin preparations Anal. Biochem. 109 1980 466
34. H.G. Garg, H. Mrabat, L. Yu, C. Freeman, B. Li, F. Zhang, R.J. Linhardt, and C.A. Hales Significance of the 2-O-sulfo group of l-iduronic acid residues in heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells Carbohydr. Res. 343 2008 2406 2410
35. Y. Kariya, M. Kyogashima, K. Suzuki, T. Isomura, T. Sakamoto, K. Horie, M. Ishihara, R. Takano, K. Kamei, and S. Hara Preparation of completely 6-O-desulfated heparin and its ability to enhance activity of basic fibroblast growth factor J. Biol. Chem. 275 2000 25949 25958
36. K. Nagasawa, Y. Inoue, and T. Kamata Solvolytic desulfation of glycosaminoglycuronan sulfates with dimethyl sulfoxide containing water or methanol Carbohydr. Res. 58 1977 47 55
37. 1H nuclear magnetic resonance spectroscopic analysis for determination of glucuronic and iduronic acids in dermatan sulfate, heparin, and heparan sulfate Anal. Biochem. 297 2001 42 51
38. A.V. Kabanov, R.I. Nazarova, I.V. Astafieva, E.V. Batrakova, V.Yu. Alakhov, A.A. Yaroslavov, and V.A. Kabanov Micelle formation and solubilization of fluorescent probes in poly(oxyethylene-b-oxypropylene-b-oxyethylene) solutions Macromolecules 28 1995 2303 2314
39. K. Akiyoshi, S. Deguchi, H. Tajima, T. Nishikawa, and J. Sunamoto Microscopic structure and thermoresponsiveness of a hydrogel nanoparticle by self-assembly of a hydrophobized polysaccharide Macromolecules 30 1997 857 861
40. W. Yeeprae, S. Kawakami, F. Yamashita, and M. Hashida Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages J. Control. Release 114 2006 193 201
41. B. Casu, G. Diamantini, G. Fedeli, M. Mantovani, P. Oreste, R. Pescador, R. Porta, G. Prino, G. Torri, and G. Zoppetti Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins Arzneimittelforschung 36 1986 637 642
42. Q. Li, and I.M. Verma NF-kappaB regulation in the immune system Nat. Rev. Immunol. 2 2002 725 734
43. R.J. Linhardt, and Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity J. Med. Chem. 46 2003 2551 2564
44. J. Bae, U.R. Desai, A. Pervin, E.E. Caldwell, J.M. Weiler, and R.J. Linhardt Interaction of heparin with synthetic antithrombin III peptide analogues Biochem. J. 301 1994 121 129
45. R.E. Hileman, R.N. Jennings, and R.J. Linhardt Thermodynamic analysis of the heparin interaction with a basic cyclic peptide using isothermal titration calorimetry Biochemistry 37 1998 15231 15237
46. J.Y. Homma, M. Matsuura, and Y. Kumazawa Structure-activity relationship of chemically synthesized nonreducing parts of lipid A analogs Adv. Exp. Med. Biol. 256 1990 101 119
47. Y. Fujimoto, Y. Adachi, M. Akamatsu, Y. Fukase, M. Kataoka, Y. Suda, K. Fukase, and S. Kusumoto Synthesis of lipid A and its analogues for investigation of the structural basis for their bioactivity J. Endotoxin Res. 11 2005 341 347
48. B.S. Park, D.H. Song, H.M. Kim, B.S. Choi, H. Lee, and J.O. Lee The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex Nature 458 2009 1191 1195